BioLargo Announces Municipal Wastewater Treatment Pilot

Rhea-AI Summary

BioLargo, Inc. (OTCQB:BLGO) has announced a municipal wastewater treatment pilot for its innovative water treatment technologies, AOS and AEC, to be conducted near Montréal, Québec. This pilot aims to validate the effectiveness and cost-efficiency of these technologies in treating challenging contaminants in real wastewater environments. Funded partly by a $225,000 CAD grant from NSERC, the project is expected to generate initial results by Q1 2021. BioLargo’s technologies previously demonstrated successful wastewater treatment capabilities at a poultry facility in Alberta.

Positive

• Pilot project for AOS and AEC technologies funded with $225,000 CAD from NSERC.
• Potential for reducing costs and enhancing efficiency in municipal wastewater treatment.

Negative

• Initial results of the pilot will only be available in Q1 2021, possibly delaying investor insights.

WESTMINSTER, CA / ACCESSWIRE / August 25, 2020 / BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, announced today that its first municipal wastewater treatment demonstration pilot of its AOS and AEC water treatment technologies will take place at a wastewater treatment plant near Montréal, Québec. Experts in water treatment and technology development from the Centre des Technologies de L'Eau (CTE) will supervise and validate the performance of the pilot on-site.

The purpose of the pilot is to assess BioLargo's proprietary water treatment technologies - the Advanced Oxidation System (AOS) and Aqueous Electrostatic Concentrator (AEC) - as effective, cost-efficient, and complementary solutions for disinfecting and eliminating a broad range of recalcitrant contaminants from municipal wastewater in an operating wastewater treatment plant. The AOS and AEC have previously been shown to effectively remove hard-to-treat contaminants such as pharmaceutical pollutants, as well as other micropollutants like per- and poly-fluoroalkyl substances (PFAS), respectively.

This new pilot comes shortly after the successful conclusion of the company's first demonstration pilot for the AOS technology at a poultry farm and processing facility near Edmonton, Alberta, where the technology was proven capable of providing effective and affordable treatment of poultry wastewater to the U.S. EPA's safe water discharge standards. In keeping with BioLargo's business plan, the company next sought to demonstrate the technology in a municipal wastewater treatment application.

The joint AOS/AEC demonstration pilot is funded in part by the Canadian Natural Science and Engineering Research Council (NSERC), through an Applied Research and Development (ARD) program grant, which will provide $225,000 CAD for the project. BioLargo's engineers and scientists are building the AOS and AEC units for the pilot, and hope to have them installed and running by the end of October. Because of the pilot's scope, the company expects to report initial results in the first quarter of 2021.

BioLargo Water President Dr. Richard Smith commented. "This is an extremely exciting pilot for us. The BioLargo AOS and AEC technologies have the potential to provide myriad benefits to municipal wastewater treatment operators, including reducing operating costs, greater breadth of treatment capabilities, and greater energy efficiency."

The CTE is a recognized college research center for technology transfer attached to the college of Saint-Laurent in Montreal, Quebec. The mission of CTE is to carry out applied research and development activities, technical assistance, and information dissemination in the field of water technologies. The pilot project is led by the CTE researcher Dr. Rimeh Daghrir, expert in the development of advanced electrochemical technology and the remediation of micro-pollutants from water.

Dr. Daghrir commented, "We are very excited to help move the AOS program along to commercialization. These pilot assays will generate real-time data to show the AOS performance in a real wastewater stream. This AOS innovative technology developed by BioLargo Water is positioned in the water treatment market as an effective and cost-efficient tool for the disinfection and the decontamination of persistent organic pollutants such as the residual of pharmaceutical products. Certainly, this advanced pilot combining AOS technology to AEC system offers an innovative and sustainable solution to problems of water conservation and high cost of industrial water use because it is an extremely powerful, safe, and cost-effective water treatment platform. Thanks to this successful collaboration with BioLargo, funded by NSERC, we have succeeded in training highly qualified experts and graduating students from the Department of Water Technology of the College Saint-Laurent in the environmental electro-technology field."

About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
During the course of the stockholder presentation, BioLargo may make "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

SOURCE: BioLargo, Inc.

View source version on accesswire.com:
https://www.accesswire.com/603164/BioLargo-Announces-Municipal-Wastewater-Treatment-Pilot

FAQ

What is the purpose of BioLargo's pilot project for AOS and AEC technologies in 2020?

The pilot project aims to validate the performance of AOS and AEC technologies in treating municipal wastewater.

Where is the municipal wastewater treatment pilot for BioLargo taking place?

The pilot is taking place near Montréal, Québec.

What funding supports BioLargo's municipal wastewater treatment pilot?

The project is supported by a $225,000 CAD grant from the Canadian Natural Science and Engineering Research Council (NSERC).

When can we expect initial results from BioLargo's wastewater treatment pilot?

Initial results from the pilot are expected to be reported in the first quarter of 2021.

What contaminants can BioLargo's AOS and AEC technologies treat?

The technologies are designed to eliminate a range of contaminants, including pharmaceuticals and PFAS.